Background and purpose: Pancreatic cancer is often diagnosed at advanced stage

therefore

chemotherapy remains the cornstone of treatment for advanced pancreatic cancer. However

no standard regimen has been established as second-line therapy for advanced pancreatic cancer. The purpose of the study was to evaluate the efficacy and safety of albumin-bound paclitaxel plus S-1 for the treatment of advanced pancreatic cancer patients in second-line setting after the failure of gemcitabine treatment. Methods: Clinical outcomes of 19 patients with advanced pancreatic cancer were analyzed. These patients received album

in-bound paclitaxel plus S-1 as second-line therapy after the failure of gemcitabine treatment. Albumin-bound paclitaxel was administered at a dose of 125 mg/m2 over 30 minutes on day 1 and 8 of a 21-day cycle. From d1-14

all patients received oral S-1 40 mg/m

2

twice daily. Results: All patients were available for evaluation. Of the 19 patients

1 case got complete response (CR)

4 cases had partial response (PR) and 9 cases had stable disease (SD). The objective response rate (ORR) was 26.3%

the disease control rate (DCR) was 73.7% and the median progression free survival (PFS) was 5.2 months. The main toxicities include hematological toxicity

myodynia

gastrointestinal reactions

sensory neuropathy

fatigue and alopecia. Conclusion: The combination of albumin-bound paclitaxel and S-1 is effective and tolerated in the treatment of advanced pancreatic cancer patients who resistant to gemcitabine.